Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Sponsor
Centre Antoine Lacassagne
Study ID
NCT00885066
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of gemcitabine given together with capecitabine and erlotinib in treating patients with advanced pancreatic cancer.

Key Dates

First listed
Apr 21, 2009
Start date
May 31, 2008
Status verified
Apr 2026
Primary completion
Sep 30, 2009
Completion
Oct 31, 2009

Study Design

Enrollment
30 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: gemcitabine, capecitabine, erlotinib

Primary Outcome Measure

Clinical or laboratory toxicities as assessed by CTC [ Time Frame: 1 year ]

Related Studies